Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 7/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.37 |
| ▸ | DRD2 | P14416 | 5/20 | 0.35 |
| ▸ | DRD3 | P35462 | 5/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493311 | 0.86 | BDKRB1 (0.41) | AVPR1ABDKRB1 | |
| SCHEMBL493414 | 0.84 | BDKRB1 (0.41) | AVPR1ADRD2DRD3BDKRB1 | |
| SCHEMBL645572 | 0.81 | AVPR1B (0.45) | AVPR1BAVPR1ABDKRB1EPHX2 | |
| SCHEMBL643968 | 0.80 | AVPR1B (0.43) | AVPR1BAVPR1ABDKRB1HTR6 | |
| SCHEMBL645571 | 0.79 | AVPR1B (0.46) | AVPR1BAVPR1A | |
| SCHEMBL642950 | 0.72 | AVPR1B (0.45) | AVPR1BAVPR1A | |
| SCHEMBL24011599 | 0.71 | NPC1 (0.58) | — | |
| SCHEMBL492977 | 0.70 | BDKRB1 (0.36) | BDKRB1 | |
| SCHEMBL643095 | 0.70 | AVPR1B (0.48) | AVPR1BAVPR1ABDKRB1HTR6 | |
| SCHEMBL2492035 | 0.69 | AVPR1B (0.46) | AVPR1BAVPR1ABDKRB1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119633-B2 | N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases | GRUENENTHAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20080312231-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312231-A1 | Substituted Sulfonamide Compounds | SULT2A1, SULT1A1, SCN1A | AVPR1B 878/4885AVPR1A 1096/4885DRD2 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.